Navigation Links
BioMarin to Present at the Deutsche Bank 2010 BioFEST Conference
Date:12/7/2010

NOVATO, Calif., Dec. 7, 2010 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank 2010 BioFEST Conference in Boston on Tuesday, December 14, 2010 at 9:00 a.m. ET.  

Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com.  A replay of the call will be archived on the site for one week following the call.

About BioMarinBioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio comprises four approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; Kuvan® (sapropterin dihydrochloride) Tablets, for phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany; and Firdapse™ (amifampridine phosphate), which has been approved by the European Commission for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Other product candidates include GALNS (N-acetylgalactosamine 6-sulfatase), which is currently in clinical development for the treatment of MPS IVA, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase II clinical development for the treatment of PKU. For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.

BioMarin®, Naglazyme® and Kuvan® are registered trademarks of BioMarin Pharmaceutical Inc.

Firdapse™ is a trademark of BioMarin Huxley Ltd.

Aldurazyme® is a registered trademark of BioMarin/Genzyme LLC.Contact:Eugenia ShenBioMarin Pharmaceutical Inc.(415) 506-6570
'/>"/>

SOURCE BioMarin Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Completes Partial Exchange of Convertible Notes Due 2013 for Common Stock
2. BioMarin Announces Third Quarter 2010 Financial Results
3. BioMarin to Host a Research and Development Day on October 19th
4. BioMarin Appoints William Young and Kenneth Bate to Its Board of Directors
5. BioMarin to Present at the UBS Global Life Sciences Conference
6. BioMarin to Present at the Stifel Nicolaus Healthcare Conference
7. BioMarin Receives Orphan Drug Designation from the FDA for BMN-701 for the Treatment of Pompe Disease
8. BioMarin Acquires ZyStor Therapeutics, Inc.
9. BioMarin Initiates Phase 3b Study to Evaluate the Effects of Kuvan on Neurophychiatric Symptoms in Subjects with PKU
10. BioMarin to Acquire LEAD Therapeutics
11. BioMarin to Present at the Credit Suisse Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ANGELES , March 22, 2017  ImaginAb Inc. today announced ... Joseph Limber , chairman of ImaginAb, said ... strong track record that is directly relevant to our business, particularly ... We believe that with his leadership, we can realize our potential." ... Mr. Coombs is ...
(Date:3/22/2017)... 22. März 2017   VWR ... tätige Anbieter von Produkten und Dienstleistungen für ... von EPL Archives Inc. bekannt, eines internationalen ... im kompletten Zyklus regulierter Forschung, Entwicklung und ... Speicherung von Dokumenten und Zusatzdienstleistungen zur Seite ...
(Date:3/22/2017)... Research and Markets has announced the addition of the ... to 2025" report to their offering. ... The Global Pharmaceutical Packaging Market is ... next decade to reach approximately $129.81 billion by 2025. ... the given segments on global as well as regional levels presented ...
Breaking Medicine Technology:
(Date:3/23/2017)... , ... March 23, 2017 , ... “Beyond and Back”: ... and Back” is the creation of published author Bonetta Rose, a wife, mother and ... lives. , Published by Christian Faith Publishing, Bonetta Rose‘s new book presents actual events ...
(Date:3/23/2017)... ... 2017 , ... Ogden Clinic, the largest multi-specialty group in ... to expand its focus on patient care by providing an advanced check-in and ... Ogden Clinic, we are working to become a different type of provider, one ...
(Date:3/23/2017)... ... 2017 , ... “More Corruption”: a simple and strong explanation of the God’s love. “More ... of Heaven was asked by God to write a book about Him. , She says, ... I kept my commitment to the Lord God. They have not walked in my shoes ...
(Date:3/22/2017)... , ... March 22, 2017 , ... ... the publication of the first issue of its companion print magazine. The new ... about cosmetic surgery thanks to information provided by board-certified doctors from across the ...
(Date:3/22/2017)... ... March 22, 2017 , ... Pinnacle ... with a robust, ongoing community enrichment program, has announced their latest charity partner. ... has provided for the critical needs of homeless families with children for thirty ...
Breaking Medicine News(10 mins):